Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036205 · ClinicalTrials.gov registry record · Phase 3
Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 984
- Enrollment target
NCT00036205: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00036205 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 984 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036205, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 984 participants
- Enrollment target
Study Summary
The primary objective is to assess the long term safety and tolerability of sumanirole as measured by safety labs, ECG monitoring, vital signs, and adverse event reports in subjects with Parkinson's Disease who participated in previous sumanirole studies.
Interventions
- DRUG sumanirole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 984 participants |
| Start Date | 2000-08 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
Why NCT00036205 stopped before completion
NCT00036205 is an interventional study that assigns participants to a tested intervention. The registered 984 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% higher).
The record links to 0 conditions, and to 1 intervention - of which sumanirole is the first listed.
NCT00036205 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036205 about?
NCT00036205 is a clinical study titled "Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease". The primary objective is to assess the long term safety and tolerability of sumanirole as measured by safety labs, ECG monitoring, vital signs, and adverse event reports in subjects with Parkinson's Disease who participated in previous sumanirole studies.
What is the current status of trial NCT00036205?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 984 participants. The study started on 2000-08. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00036205?
The interventions under investigation include: sumanirole (DRUG).
Who is sponsoring clinical trial NCT00036205?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00036205's enrollment target sits among peer trials
984 322nd of 2000 higher than 1,679 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06989437 · 982 participants · Phase 2
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- NCT06959095 · 981 participants · Phase 3
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
- NCT05079841 · 988 participants · Phase 4
The Stimulation To Induce Mothers Study
- NCT06337097 · 980 participants · NA
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia